TY - JOUR

T1 - Economics of pharmacogenetic guided treatments

T2 - Underwhelming or overstated?

AU - Hughes, Dyfrig

N1 - DAH received funding from the Medical Research Council North West Hub in Trial Methodological Research (NWHTMR) (MR/K025635/1), and is recipient of a Health and Care Research Wales Senior Research Leader award.

PY - 2018/5

Y1 - 2018/5

N2 - Economic evaluations have dispelled a perception that precision medicine, achieved through pharmacogenetic testing, reduces healthcare costs. For many tests aimed at preventing adverse drug reactions, cost‐effectiveness analyses predict modest improvements in health benefits and increases in total costs. While there are many uncertainties in estimating the value of testing, factors that influence cost‐effectiveness include the rarity of the outcome, the effectiveness of alternative treatments, and the scope and perspective of analysis.

AB - Economic evaluations have dispelled a perception that precision medicine, achieved through pharmacogenetic testing, reduces healthcare costs. For many tests aimed at preventing adverse drug reactions, cost‐effectiveness analyses predict modest improvements in health benefits and increases in total costs. While there are many uncertainties in estimating the value of testing, factors that influence cost‐effectiveness include the rarity of the outcome, the effectiveness of alternative treatments, and the scope and perspective of analysis.

U2 - 10.1002/cpt.1030

DO - 10.1002/cpt.1030

M3 - Article

VL - 103

SP - 749

EP - 751

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -